These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 483262)

  • 41. [In vitro measurement of fibrinolysis by urokinase].
    Senf L
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1981; 108(6):819-21. PubMed ID: 6176506
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The progress of a fibrinolytic therapy with streptokinase, urokinase and warfarin in a thoroughbred with intermittent lameness with special reference to resonance thrombography].
    Pause B; Nolte I; Geiss V; Mayer H; Lasch HG
    Tierarztl Prax; 1988; 16(4):377-83. PubMed ID: 3222790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Theoretic and practical considerations on laboratory monitoring of thrombolytic therapy.
    Conard J; Samama MM
    Semin Thromb Hemost; 1987 Apr; 13(2):212-22. PubMed ID: 3114887
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of fibrin and fibrinogen-degradation products on the growth of rabbit aortic smooth muscle cells in culture.
    Ishida T; Tanaka K
    Atherosclerosis; 1982 Aug; 44(2):161-74. PubMed ID: 7138618
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Experimental and clinical studies on oral urokinase and lysyl-plasminogen. Thrombolytic therapy for cerebral thrombosis].
    Naito I
    Rinsho Ketsueki; 1984 Jul; 25(7):1027-35. PubMed ID: 6389929
    [No Abstract]   [Full Text] [Related]  

  • 46. Differences in the activation rates of plasminogen by tissue plasminogen activator and urokinase.
    Takada A; Shizume K; Cho M; Takada Y
    Thromb Res; 1987 Feb; 45(4):371-81. PubMed ID: 2437668
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A role of fibrin deposits in the development of rabbit Masugi nephritis and effect of urokinase on the experimental glomerulonephritis (author's transl)].
    Akiba T; Tanaka K
    Nihon Jinzo Gakkai Shi; 1982 Feb; 24(2):125-38. PubMed ID: 7047822
    [No Abstract]   [Full Text] [Related]  

  • 48. Differential effects of activation of prothrombin by streptokinase compared with urokinase and tissue-type plasminogen activator (t-PA).
    Eisenberg PR; Miletich JP; Sobel BE; Jaffe AS
    Thromb Res; 1988 Jun; 50(5):707-17. PubMed ID: 3137687
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Conversion of proteolytically modified form (Lys-form) of human plasminogen to plasmin by urokinase in the presence of tranexamic acid.
    Takada A; Takada Y
    Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):411-9. PubMed ID: 6459659
    [No Abstract]   [Full Text] [Related]  

  • 50. Effects of pro-urokinase and urokinase on the fibrinolytic system in man.
    Trübestein G; Popov S; Wolf H; Welzel D
    Haemostasis; 1987; 17(4):238-44. PubMed ID: 2442078
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro potentiation of urokinase-activated lysis of human fibrin clots.
    Singh K; Vézina C
    J Med; 1974; 5(6):297-302. PubMed ID: 4528600
    [No Abstract]   [Full Text] [Related]  

  • 52. [State of the thrombin-plasmin system in nephrotoxic nephritis treated with heparin, urokinase, and uroplasmin].
    Monastyrskiĭ VA; Ambarova LI
    Arkh Patol; 1980; 42(1):17-22. PubMed ID: 6445726
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Studies on coagulation and fibrinolysis. III. Urokinase activated fibrinolysodynamicogram].
    Hu YM; Xue H; Wang KQ
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1982 Jun; 4(3):133-6. PubMed ID: 6215134
    [No Abstract]   [Full Text] [Related]  

  • 54. [Urokinase treatment of threatened and acute myocardial infarct].
    Babeau P; Pras P
    Ann Med Interne (Paris); 1977 Feb; 128(2):219-25. PubMed ID: 869389
    [No Abstract]   [Full Text] [Related]  

  • 55. Intraarterial urokinase produces significant attenuation of infarction volume in an embolic focal ischemia model.
    Shuaib A; Yang Y; Li Q; Siddiqui MM; Kalra J
    Exp Neurol; 1998 Dec; 154(2):330-5. PubMed ID: 9878171
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [In vitro study of a human plasmin (CY 218) and its association with urokinase (author's transl)].
    Brochier M; Griguer P
    Rev Med Brux; 1981 Mar; 2(3):167-74. PubMed ID: 6453415
    [No Abstract]   [Full Text] [Related]  

  • 57. Design and evaluation of a thrombin-activable plasminogen activator.
    Yang WP; Goldstein J; Procyk R; Matsueda GR; Shaw SY
    Biochemistry; 1994 Mar; 33(8):p606-12. PubMed ID: 8117652
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Fibrinolysis of soluble and polymerized des-AA/des-AABB fibrin compared to fibrinogenolysis in buffer and in fibrinogen-boosted serum. Evidence that plasminogen activators are responsible for preferential degradation of polymerized fibrin.
    Brosstad F
    Thromb Res; 1979; 15(3-4):497-504. PubMed ID: 158847
    [No Abstract]   [Full Text] [Related]  

  • 59. Subunits and susceptibility of fibrins formed from bovine fibrinogen by arvin, reptilase, thrombin and staphylothrombin.
    Zajdel M; Wegrzynowicz Z; Sawecka J; Kopeć M
    Thromb Res; 1975 Apr; 6(4):337-44. PubMed ID: 1169826
    [No Abstract]   [Full Text] [Related]  

  • 60. Fibrin suspension as a substrate fop plasmin: determination and kinetics.
    Kanai S; Okamoto H; Tamaura Y; Yamazaki S; Inada Y
    Thromb Haemost; 1979 Dec; 42(4):1153-8. PubMed ID: 161668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.